SBMFF News and Press, Sino Biopharmaceutical Ltd From 02/16/23

Summary The recent unprecedented national security incident created by suspected Chinese spy balloons and other aerial objects ratchet up geopolitical tensions and put F-star's acquisition by Sino Biopharmaceutical at significant risk. F-star's controversial acquisition by Sino Biopharm...

Summary HutchMed out-licensed global rights (ex-China) for a colorectal cancer therapy, fruquintinib, to Takeda Pharmaceutical in a deal worth up to $1.13 billion, including $400 million upfront. Guangzhou Akeso was approved to market penpulimab, an anti PD-1 mAb, as a first-line treatm...

Summary FSTX seems undervalued, even at the $7.12 takeover bid. The CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns. If the deal closes, the stock should rise 30%; if it fails, FSTX still has very valuable assets. The only r...

Summary The odds are now in favor of a successful completion of the Sino Biopharmaceutical/F-star merger as the UK government has approved the deal. CFIUS is the final hurdle before the deal can close. While CFIUS approval is not a slam dunk, the latest developments point towa...

Summary Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharm, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from France’s Inventiva in a $307 million deal. Immuno Cure, a Hong Kong biotech focused on DNA vaccines and immunotherapies, acq...

Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion HONG KONG, Aug 23, 2022 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177...

invoX Pharma, a Sino Biopharm subsidiary, will pay $161 million to acquire F-Star, a Cambridge, UK clinical-stage company developing bispecific drugs for immunotherapies. Xuanzhu Biopharm of Shandong out-licensed China rights for two anti-infectives to Shanghai SPH New Asia Pharma in ...

Vivo Capital, a US-China healthcare investor, held its first closing of a yuan-denominated private equity fund at $600 million, with a target of bringing the fund to $1.5 billion. SciNeuro Pharma, a Shanghai CNS company, acquired global rights to Lp-PLA2 inhibitors for neurodegenerati...

Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in a $125 million agreement. Oncotelic Therapeutics, a South San Francisco company, formed a Hong Kong JV with Dragon Overseas Capital to develop TGF-β therapeutics. ...

Broncus Holding, a Hangzhou pulmonary medical device company, completed a $200 million IPO on the Hong Kong exchange that valued the company at nearly $1.3 billion. Suzhou CStone Pharma and US-based EQRx reported their partnered PD-(L)1 antibody increased median progression-free survi...